Good Outcome for Very High Risk Adult B-cell Acute Lymphoblastic Leukaemia Carrying Genetic Abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if Promptly Submitted to Allogeneic Transplantation, after Obtaining a Good Molecular Remission

Acute lymphoblastic leukaemia (ALL) carrying t(9;22) or t(4;11) genetic abnormalities represents a very high risk subtype of disease (VHR-ALL). Hematopoietic stem cell transplantation (HSCT) remains the best curative option not only for t(4;11) ALL, but also for t(9;22) ALL in the tyrosin-kinase inh...

Full description

Saved in:
Bibliographic Details
Published in:Mediterranean journal of hematology and infectious diseases 2015, Vol.7 (1), p.e2015041-e2015041
Main Authors: Parma, Matteo, Viganò, Clara, Fumagalli, Monica, Colnaghi, Federica, Colombo, Arianna, Mottadelli, Federica, Rossi, Vincenzo, Elli, Elena, Terruzzi, Elisabetta, Belotti, Angelo, Cazzaniga, Giovanni, Pogliani, Enrico Maria, Pioltelli, Pietro
Format: Article
Language:English
Subjects:
Acute Lymphoblastic Leukemia
Bone marrow transplantation
Minimal Residual Disease
Original
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c456t-3390ba06bf24acdcb97e34399a32450c90e3d8422650e51e7e1d724cdca685783
cites
container_end_page e2015041
container_issue 1
container_start_page e2015041
container_title Mediterranean journal of hematology and infectious diseases
container_volume 7
creator Parma, Matteo
Viganò, Clara
Fumagalli, Monica
Colnaghi, Federica
Colombo, Arianna
Mottadelli, Federica
Rossi, Vincenzo
Elli, Elena
Terruzzi, Elisabetta
Belotti, Angelo
Cazzaniga, Giovanni
Pogliani, Enrico Maria
Pioltelli, Pietro
description Acute lymphoblastic leukaemia (ALL) carrying t(9;22) or t(4;11) genetic abnormalities represents a very high risk subtype of disease (VHR-ALL). Hematopoietic stem cell transplantation (HSCT) remains the best curative option not only for t(4;11) ALL, but also for t(9;22) ALL in the tyrosin-kinase inhibitors era. In the last years, low molecular level of minimal residual disease (MRD) before HSCT was reported as one of the best favourable indexes for survival in ALL. Here we observed that even these patients can show a favourable outcome if submitted to HSCT with very low MRD. We considered 18 consecutive VHR-ALL patients eligible to HSCT. 16 of them were transplanted in first remission, as soon as possible, employing myelo-ablative conditioning regimens. Molecular MRD has been evaluated before and after HSCT. Immediately before HSCT, MRD revealed: complete molecular remission (MRD(neg)) for five patients, and a level
doi_str_mv 10.4084/MJHID.2015.041
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_af5ecefb6c764378a94c334348a27b1b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_af5ecefb6c764378a94c334348a27b1b</doaj_id><sourcerecordid>1689309006</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-3390ba06bf24acdcb97e34399a32450c90e3d8422650e51e7e1d724cdca685783</originalsourceid><addsrcrecordid>eNpVkk1vEzEQhlcIRKvSK0fkYyo1wWt7vxQJKQRog1IVlcLVmvXOJm6968T2IuVX8xdwmlK1vtiaef3MePwmyfuUTgQtxcer75eLLxNG02xCRfoqOWaUZ2NOaf762fkoOfX-jsbFeVpy9jY5YjktMirK4-TvhbUNuR6Csh2S1jryG92OXOrVmtxof09mzWAC-TxWaAyZqSEgWe66zdrWBnzQiixxuAfsNJA5OLfT_YpcYI_71KzurevA6KDRkzAS0zQ9G21ZOt0yfkZisTCqpozFGBfTbUyeE92SH852m2B25OdQdzoEbEiwZGaMXUVw5N466P3GQB8gaNufE2gDOnJdB9D9vgEgD8-6sgbVYMCRm9ig91H7LnnTgvF4-rifJL--fb2dX46X1xeL-Ww5ViLLw5jzitZA87plAlSj6qpALnhVAWcio6qiyJtSMJZnFLMUC0ybgomohLzMipKfJIsDt7FwJzdOd-B20oKWDwHrVhJcnJFBCW2GCts6V0UueFFCJRSPxUQJrKjTOrI-HVibOA9sFPbBgXkBfZnp9Vqu7B8pYqt5xiJg9AhwdjugDzJOY_-h0KMdvEzzsuK0il6J0slBqpz13mH7VCalcm862d2tdSP3ppPRdPHCh-fNPcn_W4z_AzF306I</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1689309006</pqid></control><display><type>article</type><title>Good Outcome for Very High Risk Adult B-cell Acute Lymphoblastic Leukaemia Carrying Genetic Abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if Promptly Submitted to Allogeneic Transplantation, after Obtaining a Good Molecular Remission</title><source>NCBI_PubMed Central（免费）</source><source>EZB Electronic Journals Library</source><creator>Parma, Matteo ; Viganò, Clara ; Fumagalli, Monica ; Colnaghi, Federica ; Colombo, Arianna ; Mottadelli, Federica ; Rossi, Vincenzo ; Elli, Elena ; Terruzzi, Elisabetta ; Belotti, Angelo ; Cazzaniga, Giovanni ; Pogliani, Enrico Maria ; Pioltelli, Pietro</creator><creatorcontrib>Parma, Matteo ; Viganò, Clara ; Fumagalli, Monica ; Colnaghi, Federica ; Colombo, Arianna ; Mottadelli, Federica ; Rossi, Vincenzo ; Elli, Elena ; Terruzzi, Elisabetta ; Belotti, Angelo ; Cazzaniga, Giovanni ; Pogliani, Enrico Maria ; Pioltelli, Pietro</creatorcontrib><description>Acute lymphoblastic leukaemia (ALL) carrying t(9;22) or t(4;11) genetic abnormalities represents a very high risk subtype of disease (VHR-ALL). Hematopoietic stem cell transplantation (HSCT) remains the best curative option not only for t(4;11) ALL, but also for t(9;22) ALL in the tyrosin-kinase inhibitors era. In the last years, low molecular level of minimal residual disease (MRD) before HSCT was reported as one of the best favourable indexes for survival in ALL. Here we observed that even these patients can show a favourable outcome if submitted to HSCT with very low MRD. We considered 18 consecutive VHR-ALL patients eligible to HSCT. 16 of them were transplanted in first remission, as soon as possible, employing myelo-ablative conditioning regimens. Molecular MRD has been evaluated before and after HSCT. Immediately before HSCT, MRD revealed: complete molecular remission (MRD(neg)) for five patients, and a level &lt;1×10(-3) for seven patients. 100 days after HSCT we had: MRD(neg) for seven patients and a decrease for all the others after HSCT. After the tapering of immunosuppressive drugs, 13 patients reached the MRD(neg) in a median time of 8 months (range 3-16). In the intention to treat analysis, 14/18 patients are alive and disease free at the date of analysis. Overall survival and event free survival is of 78% and 66% respectively, with an average follow-up of 45 months (range 6-84) since HSCT. Early transplantation with low MRD level seems to be correlated with a favourable outcome also in VHR-ALL.</description><identifier>ISSN: 2035-3006</identifier><identifier>EISSN: 2035-3006</identifier><identifier>DOI: 10.4084/MJHID.2015.041</identifier><identifier>PMID: 26075048</identifier><language>eng</language><publisher>Italy: Università Cattolica del Sacro Cuore</publisher><subject>Acute Lymphoblastic Leukemia ; Bone marrow transplantation ; Minimal Residual Disease ; Original</subject><ispartof>Mediterranean journal of hematology and infectious diseases, 2015, Vol.7 (1), p.e2015041-e2015041</ispartof><rights>2015</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-3390ba06bf24acdcb97e34399a32450c90e3d8422650e51e7e1d724cdca685783</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450652/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450652/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4021,27921,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26075048$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Parma, Matteo</creatorcontrib><creatorcontrib>Viganò, Clara</creatorcontrib><creatorcontrib>Fumagalli, Monica</creatorcontrib><creatorcontrib>Colnaghi, Federica</creatorcontrib><creatorcontrib>Colombo, Arianna</creatorcontrib><creatorcontrib>Mottadelli, Federica</creatorcontrib><creatorcontrib>Rossi, Vincenzo</creatorcontrib><creatorcontrib>Elli, Elena</creatorcontrib><creatorcontrib>Terruzzi, Elisabetta</creatorcontrib><creatorcontrib>Belotti, Angelo</creatorcontrib><creatorcontrib>Cazzaniga, Giovanni</creatorcontrib><creatorcontrib>Pogliani, Enrico Maria</creatorcontrib><creatorcontrib>Pioltelli, Pietro</creatorcontrib><title>Good Outcome for Very High Risk Adult B-cell Acute Lymphoblastic Leukaemia Carrying Genetic Abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if Promptly Submitted to Allogeneic Transplantation, after Obtaining a Good Molecular Remission</title><title>Mediterranean journal of hematology and infectious diseases</title><addtitle>Mediterr J Hematol Infect Dis</addtitle><description>Acute lymphoblastic leukaemia (ALL) carrying t(9;22) or t(4;11) genetic abnormalities represents a very high risk subtype of disease (VHR-ALL). Hematopoietic stem cell transplantation (HSCT) remains the best curative option not only for t(4;11) ALL, but also for t(9;22) ALL in the tyrosin-kinase inhibitors era. In the last years, low molecular level of minimal residual disease (MRD) before HSCT was reported as one of the best favourable indexes for survival in ALL. Here we observed that even these patients can show a favourable outcome if submitted to HSCT with very low MRD. We considered 18 consecutive VHR-ALL patients eligible to HSCT. 16 of them were transplanted in first remission, as soon as possible, employing myelo-ablative conditioning regimens. Molecular MRD has been evaluated before and after HSCT. Immediately before HSCT, MRD revealed: complete molecular remission (MRD(neg)) for five patients, and a level &lt;1×10(-3) for seven patients. 100 days after HSCT we had: MRD(neg) for seven patients and a decrease for all the others after HSCT. After the tapering of immunosuppressive drugs, 13 patients reached the MRD(neg) in a median time of 8 months (range 3-16). In the intention to treat analysis, 14/18 patients are alive and disease free at the date of analysis. Overall survival and event free survival is of 78% and 66% respectively, with an average follow-up of 45 months (range 6-84) since HSCT. Early transplantation with low MRD level seems to be correlated with a favourable outcome also in VHR-ALL.</description><subject>Acute Lymphoblastic Leukemia</subject><subject>Bone marrow transplantation</subject><subject>Minimal Residual Disease</subject><subject>Original</subject><issn>2035-3006</issn><issn>2035-3006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkk1vEzEQhlcIRKvSK0fkYyo1wWt7vxQJKQRog1IVlcLVmvXOJm6968T2IuVX8xdwmlK1vtiaef3MePwmyfuUTgQtxcer75eLLxNG02xCRfoqOWaUZ2NOaf762fkoOfX-jsbFeVpy9jY5YjktMirK4-TvhbUNuR6Csh2S1jryG92OXOrVmtxof09mzWAC-TxWaAyZqSEgWe66zdrWBnzQiixxuAfsNJA5OLfT_YpcYI_71KzurevA6KDRkzAS0zQ9G21ZOt0yfkZisTCqpozFGBfTbUyeE92SH852m2B25OdQdzoEbEiwZGaMXUVw5N466P3GQB8gaNufE2gDOnJdB9D9vgEgD8-6sgbVYMCRm9ig91H7LnnTgvF4-rifJL--fb2dX46X1xeL-Ww5ViLLw5jzitZA87plAlSj6qpALnhVAWcio6qiyJtSMJZnFLMUC0ybgomohLzMipKfJIsDt7FwJzdOd-B20oKWDwHrVhJcnJFBCW2GCts6V0UueFFCJRSPxUQJrKjTOrI-HVibOA9sFPbBgXkBfZnp9Vqu7B8pYqt5xiJg9AhwdjugDzJOY_-h0KMdvEzzsuK0il6J0slBqpz13mH7VCalcm862d2tdSP3ppPRdPHCh-fNPcn_W4z_AzF306I</recordid><startdate>2015</startdate><enddate>2015</enddate><creator>Parma, Matteo</creator><creator>Viganò, Clara</creator><creator>Fumagalli, Monica</creator><creator>Colnaghi, Federica</creator><creator>Colombo, Arianna</creator><creator>Mottadelli, Federica</creator><creator>Rossi, Vincenzo</creator><creator>Elli, Elena</creator><creator>Terruzzi, Elisabetta</creator><creator>Belotti, Angelo</creator><creator>Cazzaniga, Giovanni</creator><creator>Pogliani, Enrico Maria</creator><creator>Pioltelli, Pietro</creator><general>Università Cattolica del Sacro Cuore</general><general>PAGEPress Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>2015</creationdate><title>Good Outcome for Very High Risk Adult B-cell Acute Lymphoblastic Leukaemia Carrying Genetic Abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if Promptly Submitted to Allogeneic Transplantation, after Obtaining a Good Molecular Remission</title><author>Parma, Matteo ; Viganò, Clara ; Fumagalli, Monica ; Colnaghi, Federica ; Colombo, Arianna ; Mottadelli, Federica ; Rossi, Vincenzo ; Elli, Elena ; Terruzzi, Elisabetta ; Belotti, Angelo ; Cazzaniga, Giovanni ; Pogliani, Enrico Maria ; Pioltelli, Pietro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-3390ba06bf24acdcb97e34399a32450c90e3d8422650e51e7e1d724cdca685783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acute Lymphoblastic Leukemia</topic><topic>Bone marrow transplantation</topic><topic>Minimal Residual Disease</topic><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Parma, Matteo</creatorcontrib><creatorcontrib>Viganò, Clara</creatorcontrib><creatorcontrib>Fumagalli, Monica</creatorcontrib><creatorcontrib>Colnaghi, Federica</creatorcontrib><creatorcontrib>Colombo, Arianna</creatorcontrib><creatorcontrib>Mottadelli, Federica</creatorcontrib><creatorcontrib>Rossi, Vincenzo</creatorcontrib><creatorcontrib>Elli, Elena</creatorcontrib><creatorcontrib>Terruzzi, Elisabetta</creatorcontrib><creatorcontrib>Belotti, Angelo</creatorcontrib><creatorcontrib>Cazzaniga, Giovanni</creatorcontrib><creatorcontrib>Pogliani, Enrico Maria</creatorcontrib><creatorcontrib>Pioltelli, Pietro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Mediterranean journal of hematology and infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parma, Matteo</au><au>Viganò, Clara</au><au>Fumagalli, Monica</au><au>Colnaghi, Federica</au><au>Colombo, Arianna</au><au>Mottadelli, Federica</au><au>Rossi, Vincenzo</au><au>Elli, Elena</au><au>Terruzzi, Elisabetta</au><au>Belotti, Angelo</au><au>Cazzaniga, Giovanni</au><au>Pogliani, Enrico Maria</au><au>Pioltelli, Pietro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Good Outcome for Very High Risk Adult B-cell Acute Lymphoblastic Leukaemia Carrying Genetic Abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if Promptly Submitted to Allogeneic Transplantation, after Obtaining a Good Molecular Remission</atitle><jtitle>Mediterranean journal of hematology and infectious diseases</jtitle><addtitle>Mediterr J Hematol Infect Dis</addtitle><date>2015</date><risdate>2015</risdate><volume>7</volume><issue>1</issue><spage>e2015041</spage><epage>e2015041</epage><pages>e2015041-e2015041</pages><issn>2035-3006</issn><eissn>2035-3006</eissn><abstract>Acute lymphoblastic leukaemia (ALL) carrying t(9;22) or t(4;11) genetic abnormalities represents a very high risk subtype of disease (VHR-ALL). Hematopoietic stem cell transplantation (HSCT) remains the best curative option not only for t(4;11) ALL, but also for t(9;22) ALL in the tyrosin-kinase inhibitors era. In the last years, low molecular level of minimal residual disease (MRD) before HSCT was reported as one of the best favourable indexes for survival in ALL. Here we observed that even these patients can show a favourable outcome if submitted to HSCT with very low MRD. We considered 18 consecutive VHR-ALL patients eligible to HSCT. 16 of them were transplanted in first remission, as soon as possible, employing myelo-ablative conditioning regimens. Molecular MRD has been evaluated before and after HSCT. Immediately before HSCT, MRD revealed: complete molecular remission (MRD(neg)) for five patients, and a level &lt;1×10(-3) for seven patients. 100 days after HSCT we had: MRD(neg) for seven patients and a decrease for all the others after HSCT. After the tapering of immunosuppressive drugs, 13 patients reached the MRD(neg) in a median time of 8 months (range 3-16). In the intention to treat analysis, 14/18 patients are alive and disease free at the date of analysis. Overall survival and event free survival is of 78% and 66% respectively, with an average follow-up of 45 months (range 6-84) since HSCT. Early transplantation with low MRD level seems to be correlated with a favourable outcome also in VHR-ALL.</abstract><cop>Italy</cop><pub>Università Cattolica del Sacro Cuore</pub><pmid>26075048</pmid><doi>10.4084/MJHID.2015.041</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2035-3006
ispartof Mediterranean journal of hematology and infectious diseases, 2015, Vol.7 (1), p.e2015041-e2015041
issn 2035-3006
2035-3006
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_af5ecefb6c764378a94c334348a27b1b
source NCBI_PubMed Central（免费）; EZB Electronic Journals Library
subjects Acute Lymphoblastic Leukemia
Bone marrow transplantation
Minimal Residual Disease
Original
title Good Outcome for Very High Risk Adult B-cell Acute Lymphoblastic Leukaemia Carrying Genetic Abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if Promptly Submitted to Allogeneic Transplantation, after Obtaining a Good Molecular Remission
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A26%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Good%20Outcome%20for%20Very%20High%20Risk%20Adult%20B-cell%20Acute%20Lymphoblastic%20Leukaemia%20Carrying%20Genetic%20Abnormalities%20t(4;11)(q21;q23)%20or%20t(9;22)(q34;q11),%20if%20Promptly%20Submitted%20to%20Allogeneic%20Transplantation,%20after%20Obtaining%20a%20Good%20Molecular%20Remission&rft.jtitle=Mediterranean%20journal%20of%20hematology%20and%20infectious%20diseases&rft.au=Parma,%20Matteo&rft.date=2015&rft.volume=7&rft.issue=1&rft.spage=e2015041&rft.epage=e2015041&rft.pages=e2015041-e2015041&rft.issn=2035-3006&rft.eissn=2035-3006&rft_id=info:doi/10.4084/MJHID.2015.041&rft_dat=%3Cproquest_doaj_%3E1689309006%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c456t-3390ba06bf24acdcb97e34399a32450c90e3d8422650e51e7e1d724cdca685783%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1689309006&rft_id=info:pmid/26075048&rfr_iscdi=true